Thymus and activation‐regulated chemokine ( <scp>TARC</scp> ) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Thymus and activation‐regulated chemokine ( TARC ) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study

Published:2022-09-20 Issue:1 Volume:200 Page:70-78
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zijtregtop Eline A. M.¹²^ORCID,Diez Claudius²,Zwaan C. Michel¹²,Veening Margreet A.²³,Beishuizen Auke¹²,Meyer‐Wentrup Friederike A. G.²

Affiliation:

1. Department of Paediatric Haematology and Oncology Erasmus Medical Centre – Sophia Children's Hospital Rotterdam The Netherlands

2. Department of Paediatric Haemato‐Oncology Princess Máxima Centre for Paediatric Oncology Utrecht The Netherlands

3. Department of Paediatric Haemato‐Oncology Amsterdam University Medical Centre, Location VUmc Amsterdam The Netherlands

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18473

Reference35 articles.

1. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial

2. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients

3. Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population‐based study during 1990–2015

4. Treatment of relapsed and refractory Hodgkin Lymphoma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CCL17, CCL22 and their receptor CCR4 in hematologic malignancies;Discover Oncology;2024-09-06

2. Minimal Residual Disease Testing for Classical Hodgkin Lymphoma: A Comprehensive Review;Critical Reviews in Oncology/Hematology;2024-09

3. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma;Cancer Research Communications;2024-07-01

4. NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker;HemaSphere;2024-06-27

5. NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker;2024-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3